The US Food and Drug Administration has cleared a novel device to be worn around the neck among athletes aged 13 years or older to help protect the brain from the consequences of repeated subconcussive impacts to the head.
In a bidirectional Mendelian randomization study, researchers used recent genome-wide association study data to further examine the relationship between multiple sclerosis and depression.
In a recent analysis of 26 trials that had examined 14 disease-modifying therapies (DMT) among patients with relapsing-remitting multiple sclerosis, researchers aimed to examine whether age impacted DMT efficacy.
Researchers aimed to shed light on COVID-19 risks, outcomes, and disparities among US individuals with dementia.
The new device is used while patients are awake to help improve muscle function in the tongue which, over time, could help prevent the tongue from collapsing backwards and hindering the airway as patients sleep.
In a new study, researchers aimed to determine whether a combination of drugs used to treat benign prostatic hyperplasia was associated with a decreased risk of developing Parkinson disease.
A new study published in Multiple Sclerosis Journal replicated prior findings indicating that cognitive function declines during a relapse among patients with multiple sclerosis.
This deep brain stimulation system—the fourth generation of the system since 2012—was approved as an adjunctive therapy for certain patients with Parkinson disease.
The guideline, which is still under review, will do away with a certain waiver requirement to allow more physicians to prescribe medication-assisted treatment for opioid use disorder.
The National Multiple Sclerosis Society has issued recommendations for the use of the COVID-19 vaccine among patients with multiple sclerosis.